Business
WILLOW ANNOUNCES APPOINTMENT OF DR. JIM LALONDE TO BOARD OF DIRECTORS
WILLOW ANNOUNCES APPOINTMENT OF DR. JIM LALONDE TO BOARD OF DIRECTORS Canada NewsWire ...
About this update from Atlas Energy Corp.
[{"type":"text","content":"\n \n \n \n WILLOW ANNOUNCES APPOINTMENT OF DR. JIM LALONDE TO BOARD OF DIRECTORS\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n Dr. Lalonde has pioneered key advancements in enzyme engineering and biocatalysis that has revolutionized chemical production, protein engineering for food and nutrition, as well as drug discovery and development leading to new\n \n \n routes to pharmaceutical actives behind blockbuster drugs\n \n \n \n \n \n CALGARY, AB\n \n and\n \n MOUNTAIN VIEW, Calif.\n \n \n ,\n \n \n Feb. 22, 2023\n \n \n /CNW/ - Willow Biosciences Inc. (\"\n \n Willow\n \n \") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients announced today the appointment of\n \n Jim Lalonde\n \n , Ph.D. as its newest independent member of the Company's Board of Directors, effective\n \n February 21, 2023\n \n .\n \n \n \n \n \n \n \n \n \n \"We are very pleased to welcome Jim to our Board,\" said Dr. Peter Seufer-Wasserthal, Willow's President and CEO. \"Jim has developed stellar R&D teams behind some of the most key advancements in enzyme engineering and biocatalysis and, in the process, revolutionized a host of industries and processes while driving increased valuations for the businesses he has been associated with over his successful career. \"His guidance will be valuable to Willow as we continue to diversify our portfolio with new partners and customers, expand our R&D capabilities, and grow revenue further to support improved company valuation.\"\n \n \n Dr. Lalonde previously served with Inscripta, a global leader in genome engineering technology, as Lead of its Microbial Digital Genome Engineering Business. Prior to that, Dr. Lalonde was Senior Vice President of R&D at Codexis, Inc., a leader in protein engineering. In his nearly 15 years at Codexis he oversaw development of more than 50 enzymes for drug manufacturing, nutrition, biotherapeutics, and molecular d...